The FDA has approved the first generic version of Teva's top branded product, multiple sclerosis drug Copaxone.
Sandoz, a German generics company owned by Novartis, received FDA approval to market a generic injectable drug containing Copaxone’s active ingredient, glatiramer acetate. The Sandoz version will be knows as Glatopa.
Teva's litigation has been extensive since a U.S. appeals court threw out the Copaxone patent in 2013, and court battles on patent issues still ongoing.
Read the Philadelphia Biz Journal article
